• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基因功能的完全丧失会导致神经内分泌癌细胞适应性受损,这是由于 HIF2α 活性过高所致。

Total loss of gene function impairs neuroendocrine cancer cell fitness due to excessive HIF2α activity.

机构信息

Division of Molecular and Cellular Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.

Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142.

出版信息

Proc Natl Acad Sci U S A. 2024 Oct;121(40):e2410356121. doi: 10.1073/pnas.2410356121. Epub 2024 Sep 25.

DOI:10.1073/pnas.2410356121
PMID:39320914
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11459182/
Abstract

Loss-of-function germline () tumor suppressor mutations cause VHL disease, which predisposes individuals to kidney cancer, hemangioblastomas, and paragangliomas. The risk that a given VHL disease family will manifest some or all these tumor types is profoundly influenced by the allele it carries. For example, almost all VHL disease families that develop paraganglioma have missense mutations. VHL families with null alleles develop kidney cancer and hemangioblastomas without a high risk of paraganglioma. The latter is surprising because the gene product, pVHL, suppresses the HIF2 transcription factor and gain-of-function HIF2 mutations are also linked to paraganglioma. Paragangliomas arise from the sympathetic or parasympathetic nervous system. Given the lack of human paraganglioma cell lines, we studied the effects of inactivating in neuroblastoma cell lines, which also arise from the sympathetic nervous system. We found that total loss of pVHL function profoundly impairs the fitness of neuroblastoma cell lines in a HIF2-dependent manner both ex vivo and in vivo. This fitness defect can be rescued by pVHL variants linked to paraganglioma, but not by pVHL variants associated with a low risk of paraganglioma. These findings suggest that HIF2 activity above a critical threshold prevents the development of paraganglioma.

摘要

胚系 () 失活肿瘤抑制基因突变导致 VHL 病,使个体易患肾癌、血管母细胞瘤和嗜铬细胞瘤。特定 VHL 病家族将表现出某些或所有这些肿瘤类型的风险,受其携带的 等位基因的深刻影响。例如,几乎所有发生嗜铬细胞瘤的 VHL 病家族都存在错义 突变。携带无效 等位基因的 VHL 家族发生肾癌和血管母细胞瘤,但无高风险的嗜铬细胞瘤。这令人惊讶,因为 VHL 基因产物 pVHL 抑制 HIF2 转录因子,功能获得性 HIF2 突变也与嗜铬细胞瘤有关。嗜铬细胞瘤起源于交感或副交感神经系统。鉴于缺乏人嗜铬细胞瘤细胞系,我们研究了在神经母细胞瘤细胞系中失活 的影响,这些细胞系也起源于交感神经系统。我们发现,pVHL 功能的完全丧失以依赖 HIF2 的方式在体外和体内严重损害神经母细胞瘤细胞系的适应性。这种适应性缺陷可以通过与嗜铬细胞瘤相关的 pVHL 变体而不是与低风险的嗜铬细胞瘤相关的 pVHL 变体来挽救。这些发现表明,HIF2 活性超过临界阈值可防止嗜铬细胞瘤的发展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03db/11459182/73130c521d92/pnas.2410356121fig05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03db/11459182/541f2a5fcc02/pnas.2410356121fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03db/11459182/00f93493afdb/pnas.2410356121fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03db/11459182/61f91c0a5552/pnas.2410356121fig03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03db/11459182/b5f66a21ed21/pnas.2410356121fig04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03db/11459182/73130c521d92/pnas.2410356121fig05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03db/11459182/541f2a5fcc02/pnas.2410356121fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03db/11459182/00f93493afdb/pnas.2410356121fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03db/11459182/61f91c0a5552/pnas.2410356121fig03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03db/11459182/b5f66a21ed21/pnas.2410356121fig04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03db/11459182/73130c521d92/pnas.2410356121fig05.jpg

相似文献

1
Total loss of gene function impairs neuroendocrine cancer cell fitness due to excessive HIF2α activity.基因功能的完全丧失会导致神经内分泌癌细胞适应性受损,这是由于 HIF2α 活性过高所致。
Proc Natl Acad Sci U S A. 2024 Oct;121(40):e2410356121. doi: 10.1073/pnas.2410356121. Epub 2024 Sep 25.
2
Nervous system involvement in von Hippel-Lindau disease: pathology and mechanisms.von Hippel-Lindau 病的神经系统受累:病理学和发病机制。
Acta Neuropathol. 2013 Mar;125(3):333-50. doi: 10.1007/s00401-013-1091-z. Epub 2013 Feb 12.
3
Parasympathetic paragangliomas are part of the Von Hippel-Lindau syndrome.副交感神经节神经瘤是 von Hippel-Lindau 综合征的一部分。
J Clin Endocrinol Metab. 2009 Nov;94(11):4367-71. doi: 10.1210/jc.2009-1479. Epub 2009 Oct 6.
4
Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.通过表达阵列分析鉴定细胞周期蛋白D1和其他与希佩尔-林道肿瘤抑制基因相关的新靶点,并研究细胞周期蛋白D1基因型作为希佩尔-林道病的修饰因子。
Cancer Res. 2002 Jul 1;62(13):3803-11.
5
Retroperitoneal paraganglioma with loss of heterozygosity of the von Hippel-Lindau gene: a case report and review of the literature.伴有冯·希佩尔-林道基因杂合性缺失的腹膜后副神经节瘤:一例报告并文献复习
Endocr J. 2022 Sep 28;69(9):1137-1147. doi: 10.1507/endocrj.EJ21-0611. Epub 2022 Apr 23.
6
Von Hippel-Lindau disease.冯·希佩尔-林道病
Annu Rev Pathol. 2007;2:145-73. doi: 10.1146/annurev.pathol.2.010506.092049.
7
Germline mutations in the new E1' cryptic exon of the gene in patients with tumours of von Hippel-Lindau disease spectrum or with paraganglioma.在患有 von Hippel-Lindau 疾病谱或副神经节瘤的患者中, 基因新的 E1' 隐蔽外显子中的种系突变。
J Med Genet. 2020 Nov;57(11):752-759. doi: 10.1136/jmedgenet-2019-106519. Epub 2020 Jan 29.
8
Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas.研究资源:转录谱分析揭示了SDHB和VHL相关嗜铬细胞瘤中不同的假缺氧特征。
Mol Endocrinol. 2010 Dec;24(12):2382-91. doi: 10.1210/me.2010-0256. Epub 2010 Oct 27.
9
VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.与2C型希佩尔-林道病相关的VHL突变会导致pVHL出现广泛的结构紊乱。
J Biol Chem. 2009 Apr 17;284(16):10514-22. doi: 10.1074/jbc.M809056200. Epub 2009 Feb 19.
10
Genotype phenotype correlation in Asian Indian von Hippel-Lindau (VHL) syndrome patients with pheochromocytoma/paraganglioma.亚洲印度裔冯·希佩尔-林道(VHL)综合征合并嗜铬细胞瘤/副神经节瘤患者的基因型与表型相关性
Fam Cancer. 2018 Jul;17(3):441-449. doi: 10.1007/s10689-017-0058-y.

本文引用的文献

1
Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.罗沙司他与红细胞生成刺激剂治疗非透析依赖或透析相关慢性肾脏病贫血患者的安全性:四项 3 期研究的汇总分析。
Adv Ther. 2023 Apr;40(4):1546-1559. doi: 10.1007/s12325-023-02433-0. Epub 2023 Feb 7.
2
Belzutifan in a Patient With VHL-Associated Metastatic Pancreatic Neuroendocrine Tumor.贝伐珠单抗在一名 VHL 相关性转移性胰腺神经内分泌瘤患者中的应用。
J Natl Compr Canc Netw. 2022 Dec;20(12):1285-1287. doi: 10.6004/jnccn.2022.7047.
3
Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer.
希佩尔-林道病:氧感应、蛋白降解和癌症的研究进展。
J Clin Invest. 2022 Sep 15;132(18):e162480. doi: 10.1172/JCI162480.
4
Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.使用缺氧诱导因子脯氨酰羟化酶抑制剂治疗慢性肾脏病贫血的未来展望。
Pharmacol Ther. 2022 Nov;239:108272. doi: 10.1016/j.pharmthera.2022.108272. Epub 2022 Aug 27.
5
Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome.贝伐珠单抗,一种有效的 HIF2α 抑制剂,在 Pacak-Zhuang 综合征中的应用。
N Engl J Med. 2021 Nov 25;385(22):2059-2065. doi: 10.1056/NEJMoa2110051.
6
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.贝伐珠单抗治疗 von Hippel-Lindau 病相关肾细胞癌
N Engl J Med. 2021 Nov 25;385(22):2036-2046. doi: 10.1056/NEJMoa2103425.
7
An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease.罗沙司他治疗慢性肾脏病相关贫血的评价。
Expert Opin Pharmacother. 2022 Jan;23(1):19-28. doi: 10.1080/14656566.2021.1993821. Epub 2021 Oct 27.
8
Targeting oncoproteins with a positive selection assay for protein degraders.利用针对蛋白质降解剂的阳性选择测定法靶向癌蛋白。
Sci Adv. 2021 Feb 5;7(6). doi: 10.1126/sciadv.abd6263. Print 2021 Feb.
9
2-Oxoglutarate-dependent dioxygenases in cancer.2- 氧戊二酸依赖的双加氧酶在癌症中的作用。
Nat Rev Cancer. 2020 Dec;20(12):710-726. doi: 10.1038/s41568-020-00303-3. Epub 2020 Oct 21.
10
Targeting the HIF2-VEGF axis in renal cell carcinoma.靶向肾细胞癌中的 HIF2-VEGF 轴。
Nat Med. 2020 Oct;26(10):1519-1530. doi: 10.1038/s41591-020-1093-z. Epub 2020 Oct 5.